Prescription abandonment climbs sharply as out-of-pocket costs rise, and prior authorization delays push more patients away. Showing cost and coverage at the point of prescribing could change whether patients ever start therapy.
News|Videos|May 20, 2025
Compounded GLP-1 RA drugs: What about prices? Are compounded drugs cheaper or more expensive than manufacturers’ versions?
Author(s)Richard Payerchin
Fact checked by: Todd Shryock
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
Advertisement
GLP-1 RA drugs have made headlines for
Advertisement
Related to this article
Dengue is no longer just a travel disease in parts of Florida. Here’s how to test, treat and report it.
HFMA proposes ‘Declaration on Healthcare Affordability and Sustainability’ as physicians and patients feel the squeeze.
Why U.S. health care needs more sources of investment, not more restrictions on private equity.
Paying membership fees with pretax employer dollars held cost growth to 0.9% a year, but the numbers come with caveats physicians should know before pitching employers.
If Medicare cuts surgeon pay, it does not follow that Medicare should also cut reimbursement for primary care.
The physician and health tech executive will argue that patients labeled "hard to reach" were never the problem.
Advertisement
Advertisement
Trending on Medical Economics
1
Florida's dengue outbreak: What physicians need to know now
2
AI system outperforms physicians on diagnostic accuracy in Microsoft study
3
Pay cuts, payer AI and the staff who keep leaving: What we heard at MGMA's 100th annual conference
4
Your AI scribe is saving you time. Is it also building the case against you?
5